Attovia Therapeutics, Inc. Common Stock (ATTO) - Total Assets
Based on the latest financial reports, Attovia Therapeutics, Inc. Common Stock (ATTO) holds total assets worth $128.35 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Attovia Therapeutics, Inc. Common Stock - Total Assets Trend (2024–2025)
This chart illustrates how Attovia Therapeutics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Also see ATTO company net worth for the company's overall valuation and market capitalisation.
Attovia Therapeutics, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Attovia Therapeutics, Inc. Common Stock's total assets of $128.35 Million consist of 94.2% current assets and 5.8% non-current assets. Review how much debt does Attovia Therapeutics, Inc. Common Stock carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 24.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2024–2025)
This chart illustrates how Attovia Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Attovia Therapeutics, Inc. Common Stock stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Attovia Therapeutics, Inc. Common Stock's current assets represent 94.2% of total assets in 2025, a decrease from 94.5% in 2024.
- Cash Position: Cash and equivalents constituted 24.2% of total assets in 2025, down from 39.9% in 2024.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2024.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Attovia Therapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of Attovia Therapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Attovia Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.39 | 13.94 | - |
| Quick Ratio | 9.39 | 13.94 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | $105.79 Million | $126.84 Million | - |
Attovia Therapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Attovia Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 6.20 |
| Asset Growth Rate (YoY) | 116.2% |
| Total Assets | $165.89 Million |
| Market Capitalization | $1.03 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Attovia Therapeutics, Inc. Common Stock's assets at a significant premium (6.20x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Attovia Therapeutics, Inc. Common Stock's assets grew by 116.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Attovia Therapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual total assets of Attovia Therapeutics, Inc. Common Stock from 2024 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $165.89 Million | +116.24% |
| 2024-12-31 | $76.72 Million | -- |
About Attovia Therapeutics, Inc. Common Stock
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of… Read more